Nanexa more than doubles after Novo Nordisk licenses PharmaShell

Novo Nordisk took exclusive worldwide rights to Nanexa's particle-coating technology for certain peptide drugs in obesity, type 2 diabetes and other cardiometabolic disease, covering up to five development programs with monthly and quarterly injections as the target.

On June 1, Camurus of Lund said Eli Lilly had exercised an option to add amylin agonists to their FluidCrystal collaboration, covering up to four Lilly compounds across three classes. Camurus is eligible for up to $290 million in upfront, development and regulatory milestones, $580 million in sales milestones, and tiered mid-single-digit royalties. FluidCrystal is a different machine: an injected lipid solution that forms a gel on contact with tissue fluid, rather than an inorganic particle coating. Weekly incretin shots already work. The next fight is over how often a patient has to take one, and over who owns the formulation that makes that possible.

Nanexa's Stockholm-listed shares did not trade on the news Thursday. As of about 7:40 a.m. Eastern, they traded at 12.38 kronor, up from Thursday's close of 5.93 kronor, after an intraday high of 15.50 kronor, the top of the 52-week range. More than 28 million shares had changed hands, against a daily average of about 811,000. Novo Nordisk's class B shares in Copenhagen were little changed at 253.20 kroner. The U.S. ADR last closed Thursday at $38.62 and was little changed in extended hours. A U.S. holder's exposure is Novo, which sits alongside Lilly.

A large ceiling, not a cash payment

Nanexa is eligible for total payments of up to €1.165 billion. Of that, €615 million is the combined bucket for an upfront payment plus development and regulatory milestones. The rest is sales milestones. The company also qualifies for low-single-digit royalties on global net sales of products developed under the agreement. Novo will lead development and commercialization.

Neither company has disclosed the size of the actual upfront payment. The €1.165 billion figure is a contingent ceiling, not cash at signing, and most of it still has to be earned in the clinic, at regulators, and then in the market.

That distinction is the whole story for Nanexa's finances. The company ended June with SEK 52.6 million in cash, after a SEK 20.5 million cash outflow in the April-June quarter, and booked SEK 1.7 million of turnover. The undisclosed upfront is the near-term cash event. Everything else in that total is optional.

Five programs, no named drugs

PharmaShell is Nanexa's atomic layer deposition platform: it encases drug particles in an ultrathin film of slow-dissolving inorganic oxides, about 30 nanometers thick, so the injection can form a depot that releases the drug over time. The commercial pitch is a high drug load in a small volume, and a longer gap between shots.

The agreement does not name the peptides. Nanexa has separately published preclinical work on a monthly, and then a quarterly, formulation of semaglutide, the active ingredient in Wegovy and Ozempic. That work used rat studies and simulations of human dosing, not clinical trials, and it does not establish that semaglutide is among Novo's five licensed programs. Amycretin and CagriSema are in the same position: possible candidates, not disclosed targets.

David Westberg, Nanexa's chief executive, called the license a chance "to successfully develop products with less frequent dosing in obesity and type 2 diabetes indications." The platform still has to do that work inside Novo's peptides, in people.

Novo has held exclusivity since December 2022, when Nanexa signed an evaluation agreement and sold the Danish company a directed share issue, with an option to negotiate a license. Nanexa already had a 2025 license-and-option agreement with Moderna. The feasibility work was public. Thursday's agreement converted that option into an exclusive commercial license.

A small check for Novo

Novo's U.S. ADR is down 34% over the past year and 23% this year; Lilly is up 59% over the past year. On Monday, September 21, Novo hosted a capital markets day that set out plans to launch more than five potential multi-blockbuster drugs by 2030. The ADR fell 8.0% that session.

Against the $171 billion of equity value implied by Novo's New York-listed ADRs at Thursday's close, even the full Nanexa ceiling is a small check. Nanexa's 191 million shares were worth SEK 1.13 billion at Thursday's close of 5.93 kronor. Against Nanexa, the ceiling is the company.

For a Novo holder, the honest read is little, yet. The license adds a platform aimed at monthly and quarterly shots, on terms that still have to be earned. Nanexa's shareholders have already marked the license. Novo's have not had to.